As one example of such interests, studies in mice showed safety and anti-AML efficacy of a dual-targeted CAR against CD13 and TIM3 [123], a known culprit of T cell exhaustion that, as mentioned above, is expressed on AML cells including putative AML stem cells [184,185]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.